Giuseppa Di Vita
Research Subjects
Giuseppa Di Vita has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Corrado Romano
Section of Clinical Biochemistry and MedicalGenetics, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy, Italy
2 shared publications Angela Magazù
University of Messina
1 shared publicationCarmelo Romano
Laboratorio di Citogenetica, Oasi Institute for Research on Mental Retardation and Brain Aging, 94018 Troina, Italy
1 shared publication- Catalda Gagliano
Unità Operativa di Malattie Neuromuscolari, IRCCS Oasi Maria SS, Troina, Italy
1 shared publication - Daniela Di Benedetto
Laboratory of Medical Genetics, I.R.C.C.S. Associazione Oasi Maria Santissima, Troina, Italy
1 shared publication - Edoardo Spina
Department of Clinical and Experimental Medicine, University of Messina, Italy
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 6 (1) , 4
6p22.3 deletion: report of a patient with autism, severe intellectual disability and electroencephalographic anomalies
The interstitial 6p deletions, involving the 6p22-p24 chromosomal region, are rare events characterized by variable phenotypes and no clear genotype-phenotype correlation has been established so far.
- 1 January 2013
- Published by Springer Nature in Molecular Cytogenetics
- Vol. 6 (1) , 4
Open Access6p22.3 deletion: report of a patient with autism, severe intellectual disability and electroencephalographic anomalies
The interstitial 6p deletions, involving the 6p22-p24 chromosomal region, are rare events characterized by variable phenotypes and no clear genotype-phenotype correlation has been established so far.
- 21 June 2007
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 30 (1) , 44-50
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting
Objective To analyse the prescribing pattern and the safety profile of different atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) during the years 2002–2003 in paediatric setting. Setting Two Child Neurology and Psychiatry Divisions of Southern Italy (University of Messina and “Oasi Institute for Research on Mental Retardation and Brain Aging” of Troina). Methods A retrospective chart review of all children and adolescents starting an incident treatment with atypical antipsychotics or SSRIs was performed. Within the first 3 months of therapy, any potential adverse drug reaction (ADR) was identified and the clinical outcome of psychotropic drug treatment was assessed. Main Outcome Measure Rate of ADR in the first 3 months of therapy with atypical antipsychotics and SSRIs in children and adolescents. Results On a total of 97 patients’ charts being reviewed, 73 (75%) concerned atypical antipsychotics and 24 (25%) SSRIs. Risperidone (N = 45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%). Overall, 50 (68%) antipsychotic users reported a total of 108 ADRs during the first 3 months of therapy, leading to drug discontinuation in 23 patients (31%). Among 24 users of SSRI, 12 (50%) received paroxetine, 6 (25%) sertraline, 5 (21%) citalopram and 1 (4%) fluoxetine. Only paroxetine users (21%) reported at least one ADR, however, none of SSRI users withdrew drug treatment within first 3 months. Conclusions ADRs occurred frequently during first 3 months of treatment with atypical antipsychotics and, to a lesser extent, with SSRIs in children and adolescents. Further investigations are urgently needed to better define the benefit/risk ratio of psychotropic medications in paediatric setting.
- 21 June 2007
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 30 (1) , 44-50
Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting
Objective To analyse the prescribing pattern and the safety profile of different atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) during the years 2002–2003 in paediatric setting. Setting Two Child Neurology and Psychiatry Divisions of Southern Italy (University of Messina and “Oasi Institute for Research on Mental Retardation and Brain Aging” of Troina). Methods A retrospective chart review of all children and adolescents starting an incident treatment with atypical antipsychotics or SSRIs was performed. Within the first 3 months of therapy, any potential adverse drug reaction (ADR) was identified and the clinical outcome of psychotropic drug treatment was assessed. Main Outcome Measure Rate of ADR in the first 3 months of therapy with atypical antipsychotics and SSRIs in children and adolescents. Results On a total of 97 patients’ charts being reviewed, 73 (75%) concerned atypical antipsychotics and 24 (25%) SSRIs. Risperidone (N = 45, 62%) was the most frequently prescribed antipsychotic drug, followed by olanzapine (24, 32%). Overall, 50 (68%) antipsychotic users reported a total of 108 ADRs during the first 3 months of therapy, leading to drug discontinuation in 23 patients (31%). Among 24 users of SSRI, 12 (50%) received paroxetine, 6 (25%) sertraline, 5 (21%) citalopram and 1 (4%) fluoxetine. Only paroxetine users (21%) reported at least one ADR, however, none of SSRI users withdrew drug treatment within first 3 months. Conclusions ADRs occurred frequently during first 3 months of treatment with atypical antipsychotics and, to a lesser extent, with SSRIs in children and adolescents. Further investigations are urgently needed to better define the benefit/risk ratio of psychotropic medications in paediatric setting.
- 1 June 2007
- Published by SAGE Publications in Genetic Testing
- Vol. 11 (2) , 124-127
A New 6-bp SOX-3 Polyalanine Tract Deletion Does Not Segregate with Mental Retardation
SOX-3 is a transcription factor expressed throughout the developing central nervous system and is involved in maintenance of pluripotency in self-renewing stem cells, specification events, lineage progression, and terminal differentiation. An association between growth hormone deficiency, mental retardation, and Sox-3 mutations in humans was previously reported. The occurrence of abnormalities affecting the polyalanine tract of the Sox-3 gene was determined in a group of 77 unrelated mentally retarded patients without a definite genetic diagnosis and in 84 control subjects. A new SOX-3 polyalanine tract deletion was identified in a mentally impaired boy, in his mother (homozygous), and in 2 healthy brothers of the proband. This new mutation does not segregate with mental retardation.
- 1 June 2007
- Published by SAGE Publications in Genetic Testing
- Vol. 11 (2) , 124-127
A New 6-bp SOX-3 Polyalanine Tract Deletion Does Not Segregate with Mental Retardation
SOX-3 is a transcription factor expressed throughout the developing central nervous system and is involved in maintenance of pluripotency in self-renewing stem cells, specification events, lineage progression, and terminal differentiation. An association between growth hormone deficiency, mental retardation, and Sox-3 mutations in humans was previously reported. The occurrence of abnormalities affecting the polyalanine tract of the Sox-3 gene was determined in a group of 77 unrelated mentally retarded patients without a definite genetic diagnosis and in 84 control subjects. A new SOX-3 polyalanine tract deletion was identified in a mentally impaired boy, in his mother (homozygous), and in 2 healthy brothers of the proband. This new mutation does not segregate with mental retardation.